17,322 Shares in Harmony Biosciences Holdings, Inc. $HRMY Acquired by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,322 shares of the company’s stock, valued at approximately $631,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Chase Investment Counsel Corp bought a new position in Harmony Biosciences in the 2nd quarter worth $1,820,000. Aurora Investment Counsel purchased a new stake in Harmony Biosciences in the second quarter worth about $2,372,000. Virtus Advisers LLC purchased a new stake in Harmony Biosciences in the second quarter worth about $1,065,000. Deutsche Bank AG bought a new position in shares of Harmony Biosciences in the second quarter worth about $3,700,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Harmony Biosciences in the first quarter worth about $1,030,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Up 3.9%

Shares of HRMY opened at $42.86 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.48 and a quick ratio of 3.45. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 13.92, a price-to-earnings-growth ratio of 0.38 and a beta of 0.93. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $43.02. The business’s 50 day simple moving average is $37.31 and its 200-day simple moving average is $32.89.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.32. The company had revenue of $261.28 million for the quarter, compared to analysts’ expectations of $250.77 million. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. Harmony Biosciences’s quarterly revenue was up 30.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.92 earnings per share. As a group, equities analysts expect that Harmony Biosciences Holdings, Inc. will post 3.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HRMY shares. Wolfe Research started coverage on Harmony Biosciences in a research note on Wednesday, August 26th. They set an “outperform” rating and a $60.00 price objective for the company. Truist Financial raised their target price on shares of Harmony Biosciences from $29.00 to $34.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Zacks Research lowered shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Finally, Wall Street Zen raised shares of Harmony Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 16th. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Harmony Biosciences has an average rating of “Hold” and an average target price of $47.11.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.